Long-term survival in patients with advanced non–small-cell lung cancer treated with atezolizumab versus docetaxel: Results from the randomised phase III OAK study-Reference-Cited by-同舟云学术

Long-term survival in patients with advanced non–small-cell lung cancer treated with atezolizumab versus docetaxel: Results from the randomised phase III OAK study

Published:2019-01 Issue: Volume:107 Page:124-132
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

von Pawel J.,Bordoni R.,Satouchi M.,Fehrenbacher L.,Cobo M.,Han J.Y.,Hida T.,Moro-Sibilot D.,Conkling P.,Gandara D.R.,Rittmeyer A.,Gandhi M.,Yu W.,Matheny C.,Patel H.,Sandler A.,Ballinger M.,Kowanetz M.,Park K.

Funder

F. Hoffmann-La Roche

Publisher

Elsevier BV

Reference20 articles.

1. Cancer statistics, 2017;Siegel;CA Cancer J Clin,2017

2. Cancer treatment and survivorship statistics, 2016;Miller;CA Cancer J Clin,2016

3. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients;Herbst;Nature,2014

4. Molecular pathways: next-generation immunotherapy–inhibiting programmed death-ligand 1 and programmed death-1;Chen;Clin Canc Res,2012

5. Oncology meets immunology: the cancer-immunity cycle;Chen;Immunity,2013

Cited by 94 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment of Advanced NSCLC Patients with an Anti-Idiotypic NeuGcGM3-Based Vaccine: Immune Correlates in Long-Term Survivors;Biomedicines;2025-05-06

2. CBNPC avancés présentant un contrôle prolongé sous immunothérapie : Cohorte BREATH;Revue des Maladies Respiratoires;2025-05

3. PD-1/PD-L1 blockade therapy with atezolizumab: a new paradigm in the treatment of non-small cell lung cancer (NSCLC);Discover Oncology;2025-03-26

4. Clinical benefit of PD-1/PD-L1 inhibitors for poor performance status patients with advanced non-small cell lung cancer;Journal of Chemotherapy;2025-03-24

5. A Novel DNA Repair‐Gene Model to Predict Responses to Immunotherapy and Prognosis in Patients With EGFR‐Mutant Non‐Small Cell Lung Cancer;Thoracic Cancer;2025-02